<DOC>
	<DOC>NCT01042769</DOC>
	<brief_summary>This double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with recent acute coronary syndrome (ACS) and type 2 diabetes mellitus. Patients will be randomized to receive either aleglitazar or placebo once daily as oral doses. The study will last until at least 950 events occur, but time on study treatment will be for at least 2.5 years.</brief_summary>
	<brief_title>A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Adults &gt;18 years of age Type 2 diabetes mellitus Hospitalization for ACS event and randomization between hospital discharge and 8 weeks after the ACS index event (day of hospitalization) Estimated glomerular filtration rate &lt;45 mL/min/1.73m2 Concomitant treatment with a thiazolidinedione and/or fibrate Triglycerides &gt;400 mg/dL Anaemia Symptomatic congestive heart failure classified as New York Heart Association (NYHA) class IIIV (France and Germany: Symptomatic congestive heart failure classified as NYHA class IIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>